About: pharmaceuticals
Jourová slams Europe’s ‘morbid dependency’ on China
European Commission vice-president Věra Jourová on Sunday (19 April) chided the EU for what she said was its "morbid dependency" on China and India for medical supplies, a situation highlighted by the coronavirus crisis.Pharma incentives reform is for the next Commission, EU official says
Stakeholders gathered in the European Public Health Alliance (EPHA) reiterated their demands to reform the incentives for pharmaceutical innovation, making a set of recommendations to the European Commission during an event in Brussels on Monday (3 June).Europe’s health sector worried about post-Brexit investment dearth
Fragmented, multilingual and over-regulated: Europe is currently not an attractive place for investors and things could get worse after Brexit, experts from the life sciences industry have warned.Bayer loses €16 bln market value as concerns mount over further damages claims
Bayer shares registered yet another sharp decrease on Thursday (16 August), dropping as much as 6.5% in Frankfurt to hover near the 76 euros level as investors fear the German chemicals and pharmaceuticals giant may face numerous litigations in the US after its controversial merger with Monsanto.Pharma firms face multi-million Brexit bill, MPs warned
Pharmaceutical companies face a multi-million euro bill in regulatory costs regardless of whether the UK reaches a ‘soft’ or ‘hard’ Brexit deal with the European Union, industry leaders warned on Tuesday (19 December).New Commission study fuels generic drugs industry ‘manufacturing dispute’
The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.Patients: ‘Think carefully’ before questioning orphan drugs’ incentives
Organisations of patients with rare diseases have warned EU policymakers to “think carefully” before reviewing the incentives in the orphan drugs regulation, claiming that the pharma industry should not be discouraged from investing in new therapies.Pharma innovation
Hit hard by austerity, the health systems of EU member states are under huge pressure. Combined with an aging population and the alarming burden of chronic illnesses, EU member states have targeted specific aspects of the incentives granted to the pharma industry in order to decrease drug prices.Pharma boss: Targeting drugs won’t make healthcare systems more sustainable
“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.Anti-monopolies economist: ‘Innovation breeds inequality’
Inequality is an inevitable side effect of innovation and many monopolies could be broken by simply eliminating patents, insists Italian economist Michele Boldrin. EURACTIV’s partner El País – Planeta Futuro reports.Commission silent over Hungary’s pharmacy ownership law
EXCLUSIVE / An EU infringement procedure launched against Hungary about a law that regulates pharmacies has been unjustifiably stalled for more than two years, raising concerns among foreign investors. VideoPromoted content